Iptacopan is a complement factor B inhibitor targeting the overactive alternative complement pathway in IgA nephropathy.

The phase 2 ASSIST trial showed that atrasentan has an additional antiproteinuric effect -- approximately 25% -- over 12 weeks in patients with earlier-stage IgA nephropathy already receiving ...

GlobalData anticipates notable growth in the head and neck squamous cell carcinoma (HNSCC) market by 2034, at a CAGR of 8.4%.

The Share Consolidation is intended to increase the per share trading price of the Common Stock to enable the Company to ...

Bicara Therapeutics is well-capitalized, with over $414.8M in cash and funding runway into H1 2029, but faces competitive ...

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American ...

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta gr ...

The relationship between cardiovascular dysfunction and renal impairment is widely recognized as the cardiorenal interaction, ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

A 65-year-old man with hypertension, type 2 diabetes, a remote myocardial infarct, and chronic kidney disease (CKD) presents for routine follow-up with his family physician. Two years prior, the ...

View post: Ford Crown Victoria Fans Have Been Asking the Wrong Person For Its Comeback Tires significantly impact a car’s efficiency, performance, and driving experience. Michelin’s Primacy 5 Energy ...